- Home
- IGMS vs IPA Comparison
IGMS vs IPA Comparison
Compare IGMS & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- IPA
- Stock Information
- Founded
- IGMS 1993
- IPA 1983
- Country
- IGMS United States
- IPA United States
- Employees
- IGMS N/A
- IPA N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- IPA Health Care
- Exchange
- IGMS Nasdaq
- IPA Nasdaq
- Market Cap
- IGMS 81.9M
- IPA 74.6M
- IPO Year
- IGMS 2019
- IPA 2017
- Fundamental
- Price
- IGMS $1.27
- IPA $2.16
- Analyst Decision
- IGMS Hold
- IPA Strong Buy
- Analyst Count
- IGMS 8
- IPA 2
- Target Price
- IGMS $6.00
- IPA $4.00
- AVG Volume (30 Days)
- IGMS 1.3M
- IPA 2.1M
- Earning Date
- IGMS 08-13-2025
- IPA 09-15-2025
- Dividend Yield
- IGMS N/A
- IPA N/A
- EPS Growth
- IGMS N/A
- IPA N/A
- EPS
- IGMS N/A
- IPA N/A
- Revenue
- IGMS $2,681,000.00
- IPA $16,581,105.00
- Revenue This Year
- IGMS $252.44
- IPA $4.67
- Revenue Next Year
- IGMS $46.48
- IPA $14.15
- P/E Ratio
- IGMS N/A
- IPA N/A
- Revenue Growth
- IGMS 27.36
- IPA 1.34
- 52 Week Low
- IGMS $0.92
- IPA $0.27
- 52 Week High
- IGMS $22.50
- IPA $2.41
- Technical
- Relative Strength Index (RSI)
- IGMS 48.73
- IPA 66.79
- Support Level
- IGMS $1.26
- IPA $1.61
- Resistance Level
- IGMS $1.37
- IPA $1.85
- Average True Range (ATR)
- IGMS 0.03
- IPA 0.30
- MACD
- IGMS -0.01
- IPA 0.02
- Stochastic Oscillator
- IGMS 8.33
- IPA 73.68
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.